GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (FRA:BGLA) » Definitions » Capex-to-Operating-Income

BioGaia AB (FRA:BGLA) Capex-to-Operating-Income : 0.07 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

BioGaia AB's Capital Expenditure for the three months ended in Sep. 2024 was €-0.25 Mil. Its Operating Income for the three months ended in Sep. 2024 was €3.65 Mil.

Hence, BioGaia AB's Capex-to-Operating-Income for the three months ended in Sep. 2024 was 0.07.


BioGaia AB Capex-to-Operating-Income Historical Data

The historical data trend for BioGaia AB's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Capex-to-Operating-Income Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.07 0.03 0.05 0.11

BioGaia AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.18 0.06 0.02 0.07

Competitive Comparison of BioGaia AB's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Capex-to-Operating-Income falls into.



BioGaia AB Capex-to-Operating-Income Calculation

BioGaia AB's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-4.355) / 39.447
=0.11

BioGaia AB's Capex-to-Operating-Income for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.247) / 3.649
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioGaia AB  (FRA:BGLA) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


BioGaia AB Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB Headlines

No Headlines